Results 111 to 120 of about 15,003 (219)

Lipoic acid functions in Paneth cells to prevent human intestinal stem cell aging

open access: yesNature Communications
Intestinal stem cell (ISC) aging diminishes the regenerative capacity of the intestinal epithelia, but effective therapeutic strategies to counteract human ISC aging remain elusive.
Zehong Zhang   +16 more
doaj   +1 more source

Endogenous Amplification of Apoptosis via p53 Regulation using a Cascade Nanocatalytic Medicine

open access: yesAdvanced Science, Volume 13, Issue 19, 2 April 2026.
An engineered MOF nanomedicine (MAL) triggers cascade nanocatalysis in tumors, converting H2O2 and L‐Arg into cytotoxic peroxynitrite. This induces DNA damage, activates the p53 pathway, and amplifies mitochondrial apoptosis via the BAX/Bcl‐2/Caspase‐3 axis, effectively inhibiting colorectal cancer growth with high biocompatibility.
Tan Wu   +8 more
wiley   +1 more source

Optimizing the integration of modern systemic therapies and advanced radiotherapy techniques in breast cancer management: An expert opinion from the Institut Curie Breast Radiotherapy Group

open access: yesInternational Journal of Cancer, Volume 158, Issue 7, Page 1775-1784, 1 April 2026.
Abstract The integration of modern systemic therapies with radiotherapy (RT) represents a promising strategy in breast cancer management, enhancing both locoregional control and systemic disease outcomes. This expert consensus from the Institut Curie Breast Radiotherapy Group focuses exclusively on modern systemic agents, synthesizing current evidence ...
Cezara Cheptea   +5 more
wiley   +1 more source

Clinical validation of a DNA methylation biomarker associated with overall survival of relapsed ovarian cancer patients

open access: yesInternational Journal of Cancer, Volume 158, Issue 7, Page 1821-1835, 1 April 2026.
What's new? Most patients with ovarian cancer (OC) relapse after first‐line chemotherapy, and prognosis with second‐line treatment depends largely on the platinum‐free interval. However, reliable biomarkers to predict response to second‐line therapy remain lacking.
Muhammad Habiburrahman   +7 more
wiley   +1 more source

Reprogramming SREBP1‐dependent lipogenesis and inflammation in high‐risk breast with licochalcone A: A novel path to cancer prevention

open access: yesInternational Journal of Cancer, Volume 158, Issue 7, Page 1927-1940, 1 April 2026.
What's new? Endocrine drugs repurposed from treatment protocols are the primary medications available for breast cancer (BC) prevention in at‐risk women. Adverse effects, however, significantly minimize uptake and prevention impact. Here, the authors investigated licochalcone A (LicA), a non‐endocrine anti‐inflammatory agent with reported hematologic ...
Atieh Hajirahimkhan   +14 more
wiley   +1 more source

Anti‐Cancer Effect of a New 5‐FU Derivative Containing Triazole‐Bearing Mannose (5‐FUD‐MAN) Against Human Breast Cancer Cells Through LC3B‐Mediated Cell Death

open access: yesJournal of Biochemical and Molecular Toxicology, Volume 40, Issue 4, April 2026.
The anticancer activity of 5‐FU modified with mannose containing 1,2,3‐triazole compound in MCF‐7 breast cancer cells were revealed in this study. While 5‐FU caused cytotoxicity in both cancerous and healthy cells, 5‐FUD‐Man showed selective cytotoxicity.
Ebru Şanci   +7 more
wiley   +1 more source

The Flavivirus NS3 Protein: Its Multifaceted Roles and Therapeutic Potential

open access: yesJournal of Medical Virology, Volume 98, Issue 4, April 2026.
Abstract Mosquito‐borne flaviviruses are important human pathogenic viruses and can cause an array of symptoms ranging from asymptomatic to mild illness but can progress to severe disease conditions. Prominent members of the family Flaviviridae include Dengue virus, Zika virus, and West Nile virus, whose spread has increased globally due to the ...
Haejeong Lee, Hee Cho, Michaela U. Gack
wiley   +1 more source

Results and Exploratory Biomarker Analyses of a Phase II Study CHANGEABLE: Combination of PD‐1 Inhibitor and Niraparib in GErm‐Line‐mutAted Metastatic Breast Cancer

open access: yesMedComm, Volume 7, Issue 4, April 2026.
This phase II trial evaluated the efficacy and safety of niraparib combined with HX008 in metastatic breast cancer (MBC) patients with germline DNA damage response (DDR) gene mutations. This chemotherapy‐free regimen demonstrates promising efficacy and a tolerable safety profile in MBC patients with germline DDR mutations, providing a novel therapeutic
Jian Zhang   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy